Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12
- PMID: 9570556
Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12
Abstract
Previous studies have demonstrated eradication of small (4-8 mm) established murine MCA207 sarcomas by treatment with systemic IL-12. Analysis of the mechanism has revealed a cellular and molecular immune response at the tumor typical of a Th1 cell-mediated, macrophage-effected, delayed-type hypersensitivity (DTH) response. In the current study we investigate the immune response against long term established, large MCA207 tumors induced by combined treatment with IL-12 and cyclophosphamide (Cy), an agent known to potentiate the DTH response. Our results demonstrate that s.c. large MCA207 tumors (15-20 mm) that are refractory to treatment by either IL-12 or Cy alone can be completely eradicated by the combination of Cy and IL-12. IL-12 is apparently the only cytokine capable of mediating tumor eradication, and the effect is dependent on IFN-gamma. The contribution of Cy is probably due to immunopotentiation of DTH rather than to direct cytotoxicity to the tumor. The regression of these large tumors takes >4 wk and, in many cases, is self-sustained, in that little or no additional IL-12 is needed beyond the initial week of administration. Analysis of the cellular and molecular events at the tumor site suggests that the mechanism is a Th1-mediated antitumor immune response.
Similar articles
-
The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.Cancer Res. 2002 Aug 15;62(16):4696-703. Cancer Res. 2002. PMID: 12183428
-
Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.Cancer Res. 2002 Sep 1;62(17):5069-75. Cancer Res. 2002. PMID: 12208763
-
Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.J Immunol. 1998 Dec 15;161(12):6977-84. J Immunol. 1998. PMID: 9862733
-
Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.Curr Drug Targets. 2001 Jun;2(2):197-212. doi: 10.2174/1389450013348597. Curr Drug Targets. 2001. PMID: 11469719 Review.
-
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.Crit Rev Immunol. 2008;28(2):109-26. doi: 10.1615/critrevimmunol.v28.i2.20. Crit Rev Immunol. 2008. PMID: 18540827 Review.
Cited by
-
Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice.Immun Ageing. 2023 May 11;20(1):20. doi: 10.1186/s12979-023-00344-w. Immun Ageing. 2023. PMID: 37170231 Free PMC article.
-
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses.Vaccines (Basel). 2022 Jun 14;10(6):944. doi: 10.3390/vaccines10060944. Vaccines (Basel). 2022. PMID: 35746552 Free PMC article.
-
Interleukin-12 as an in situ cancer vaccine component: a review.Cancer Immunol Immunother. 2022 Sep;71(9):2057-2065. doi: 10.1007/s00262-022-03144-1. Epub 2022 Jan 13. Cancer Immunol Immunother. 2022. PMID: 35024897 Free PMC article. Review.
-
A multipurpose brachytherapy catheter to enable intratumoral injection.Brachytherapy. 2021 Jul-Aug;20(4):900-910. doi: 10.1016/j.brachy.2020.10.012. Epub 2021 Mar 27. Brachytherapy. 2021. PMID: 33785280 Free PMC article.
-
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.BMC Cancer. 2016 Aug 22;16(1):665. doi: 10.1186/s12885-016-2701-7. BMC Cancer. 2016. PMID: 27549240 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous